The real options approach to valuation - Haskayne School of Business

More documents

Recommendations

Info

Contract Specifics • Developer retains right, supplies monopoly quan*ty – Full discre*onary research grant – Sponsor co-‐payment – Patent extension • Sponsor can contract the socially op*mal quan*ty to be produced – Purchase commitment contracts • We abstract from agency problem arising from asymmetric informa*on between vaccine developer and sponsor, and from contrac*ng issues
We seek to answer five cri*cal ques*ons • What is the required level of monetary incen*ve to induce the firm to undertake the vaccine R&D? • What are the expected price, quan*ty supplied and efficacy of the developed vaccine? • What is the probability that a viable vaccine will be developed? • What is the consumer surplus generated? • What is the expected cost per individual successfully vaccinated?
Page 1 and 2:
The Real Op*ons Approach to Va
Page 3 and 4:
Outline of Talk • Basic ideas
Page 6 and 7:
Using Real Op*ons • Uncertainty
Page 8 and 9:
Investment Projects as Op*ons 3.
Page 10 and 11:
Risk Neutral Valua*on • Lets f
Page 12 and 13:
Certainty Equivalent Approach NPV
Page 14 and 15:
Tradi*onal vs. CE Valua*on Tradi
Page 16 and 17:
• If markets are complete (al
Page 19 and 20:
Using the Risk Neutral Framewor
Page 21 and 22:
True and risk neutral stochas*c
Page 23 and 24:
Real Op*ons Valua*on (3) • Nee
Page 25 and 26:
Solu*on Procedures
Page 27 and 28:
Solu*on Methods (2) • Par*al d
Page 29 and 30:
Valuing American Op*ons by Simu
Page 31 and 32:
Valuing American Op*ons by Simu
Page 36 and 37:
Three Factor Model: Actual (Cort
Page 38 and 39: 30.00Oil Futures 01/08/99Three-Fact
Page 40 and 41: What to do for longer maturi*e
Page 43: NYMEX crude-‐oil futures and
Page 47 and 48: Procedure • We factor analyze
Page 50 and 51: Two Vola*lity Factors (SV2)
Page 52 and 53: Expropria*on Op*on • We value
Page 54 and 55: Assump*ons • We abstract from
Page 56 and 57: Main Results • For a given co
Page 58 and 59: R&D Investments • The pharmaceu
Page 60 and 61: Analysis of R&D projects is a
Page 62 and 63: Research Spending Per New Drug Comp
Page 64 and 65: Mediva*on, Pfizer end work on A
Page 66 and 67: R&D Valua*on 1. Evalua*on of Res
Page 68 and 69: Real Op*ons Approach • Treat t
Page 70 and 71: Patent-protected R&D ProjectInvest
Page 72 and 73: Cash Flow Uncertainty Cash flow
Page 74 and 75: Stochas*c process for the (true
Page 78 and 79: Figure 4:Critical Values for Invest
Page 82 and 83: Compe**on in R&D projects • Co
Page 84 and 85: Current Literature on “Encourag
Page 86 and 87: What’s new in this paper? •
show all

The real options approach to valuation - Haskayne School of Business

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?